Aurion Biotech have announced their preliminary findings from its IOTA trail which was conducted in November 2020 and May 2021. 50 patients who have been diagnosed with corneal endothelial disease were treated with a transformational cell therapy procedure which were developed by Professor Shigeru Kinoshita and colleagues at Kyoto Prefecture University of Medicine.
The trail is the first corneal endothelial cell therapy procedure to be performed successfully outside of Japan. “This is a landmark moment for the treatment of corneal endothelial disease” Dr Edward J. Holland, Chief Medical Advisor at Aurion Biotech.
In their first trial, 16 patients were treated from a single donor, whilst in the second trial, 34 patients were treated from a single donor. The procedure is minimally invasive for patients and accessible for surgeons.
“The IOTA trial has given us invaluable clinical insights and confirms that this procedure can restore vision to patients suffering from blindness resulting from corneal endothelial disease” Greg Kunst, CEO Aurion Biotech.
Patients will be monitored overtime in order to assess the safety and efficacy of the cell treatment therapy.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.